Primary endpoints | Ability to recruit patients to the trial |
Feasibility of performing RIPC in liver transplant recipients | |
Safety of RIPC in liver transplant recipients | |
Secondary endpoints | AST levels on the third post-operative day [30] |
Incidence of acute kidney injury and need for renal replacement therapy | |
Length of stay in intensive care and total hospital stay | |
Incidence of vascular thrombotic events | |
Incidence of biliary complications | |
Incidence of post-operative infections | |
Incidence of acute rejection in the first months post transplantation | |
Circulating cytokine levels 2 h post reperfusion of the liver graft | |
T cell accumulation and activation in the liver 2 h post reperfusion | |
Urinary and serum NGAL levels 2 h post reperfusion |